Stock AnalizSTERIS plc STE
Industrial Specialties · data as of November 13, 2026
STERIS plc (STE) is a healthcare company listed in the US with a market value of about $25.7B. In the twelve months to September 30, 2026 it had revenue of $6.2B and net income of $827M, a net margin of 13.4%.
Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a P/E of 31.4, a price to free cash flow of 27.4, 5-year revenue growth of 14% a year, a 5-year average ROIC of 7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 43% below the current price.
Score: 3.0 / 5
Checks passed
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.2B | $5.9B | $5.5B | $5.1B | $4.5B | $4.2B | $3.1B | $3.0B | $2.8B | $2.6B | $2.6B |
| Net income | $827M | $782M | $615M | $378M | $107M | $244M | $397M | $408M | $304M | $291M | $110M |
| Free cash flow | $937M | $972M | $778M | $613M | $395M | $397M | $450M | $376M | $350M | $292M | $251M |
| EPS (diluted) | $8.42 | $7.93 | $6.20 | $3.81 | $1.07 | $2.48 | $4.63 | $4.76 | $3.55 | $3.39 | $1.28 |
| Net margin | 13.4% | 13.2% | 11.3% | 7.4% | 2.4% | 5.8% | 12.8% | 13.5% | 10.9% | 11.1% | 4.2% |
| ROIC | — | 8.9% | 7.6% | 6.8% | 6.9% | 3.8% | 7.4% | 9.6% | 7.8% | 7.3% | 4.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $281.14, 6% above the current price; targets range from $244.00 to $305.00; the consensus rating is “Buy”; expected EPS is $11.44 for the fiscal year ending March 31, 2027.
Frequently asked questions
What is STERIS’s P/E ratio?
About 31.4, based on the last twelve months of diluted earnings per share (forward P/E about 21.7).
Is STERIS stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 43% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does STERIS pay a dividend?
Yes. The dividend yield is about 1.04%, and it has paid dividends for 10 years in our data.
Is STERIS a good stock to buy?
We do not give buy or sell advice. STERIS scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.